LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.63 11.69

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.25

Max

3.65

Chiffres clés

By Trading Economics

Revenu

1.9M

-68M

Ventes

-5.8M

42M

Marge bénéficiaire

-163.26

Employés

570

EBITDA

25M

-41M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+23.63% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

60M

1.1B

Ouverture précédente

-8.06

Clôture précédente

3.63

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 nov. 2025, 17:45 UTC

Résultats
Principaux Mouvements du Marché

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 nov. 2025, 17:31 UTC

Résultats
Principaux Mouvements du Marché

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14 nov. 2025, 16:15 UTC

Principaux Mouvements du Marché

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14 nov. 2025, 23:56 UTC

Acquisitions, Fusions, Rachats

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 nov. 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 nov. 2025, 22:35 UTC

Résultats
Acquisitions, Fusions, Rachats

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 nov. 2025, 22:32 UTC

Acquisitions, Fusions, Rachats

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 nov. 2025, 22:29 UTC

Résultats

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 nov. 2025, 22:00 UTC

Acquisitions, Fusions, Rachats

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 nov. 2025, 21:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

14 nov. 2025, 21:18 UTC

Acquisitions, Fusions, Rachats

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 nov. 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 nov. 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 nov. 2025, 20:17 UTC

Acquisitions, Fusions, Rachats

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 nov. 2025, 19:29 UTC

Market Talk
Résultats

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 nov. 2025, 18:44 UTC

Market Talk
Résultats

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 nov. 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 nov. 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 nov. 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 nov. 2025, 17:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

14 nov. 2025, 17:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

14 nov. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 nov. 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 nov. 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14 nov. 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14 nov. 2025, 16:30 UTC

Acquisitions, Fusions, Rachats

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14 nov. 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14 nov. 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14 nov. 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14 nov. 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

23.63% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  23.63%

Haut 5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat